Although there have been no recent approvals of oral JAK inhibitors (JAK-i) for atopic dermatitis (AD), some interesting study findings have been published. These shed light on the safety of baricitinib, abrocitinib and upadacitinib with reference to the EMA opinion on JAK-i issued some time ago. In the EU, baricitinib has now been given an extended indication for AD patients aged 2 years and older.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- Long-term study with dementia patients
Ginkgo biloba extract significantly reduces the risk of progression
- Intestinal microbiome
Complex and fragile system of microorganisms
- Cancer prevention
Poorer prognosis for men who avoid prostate cancer screening
- Liver steatosis with metabolic dysfunction
New nomenclature for non-alcoholic fatty liver disease
- Diabetes mellitus
Treatment of comorbidities in older people
- Type 2 diabetes: PAD and diabetic foot syndrome
Prevention is better than cure – don’t miss the risk foot
- Prostate cancer
High-resolution ultrasound could diagnose prostate cancer faster
- Chronic lung diseases